Books+ Search Results

Meta-Analysis: Risk of Tics with Psychostimulant Use in Randomized, Placebo-Controlled Trials

Title
Meta-Analysis: Risk of Tics with Psychostimulant Use in Randomized, Placebo-Controlled Trials [electronic resource].
ISBN
9781369085303
Physical Description
1 online resource (80 p.)
Local Notes
Access is available to the Yale community.
Notes
Source: Dissertation Abstracts International, Volume: 78-03(E), Section: B.
Adviser: Michael H. Bloch.
Access and use
Access restricted by licensing agreement.
Summary
Clinical practice currently restricts the use of psychostimulant medications in children with tics or a family history of tics for fear that tics will develop or worsen as a side effect of treatment. Our goal was to conduct a meta-analysis to examine the risk of new onset or worsening of tics as an adverse event of psychostimulants in randomized, placebo-controlled trials.
We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled trials examining the efficacy of psychostimulant medications in the treatment of children with attention-deficit/hyperactivity disorder (ADHD). We used a fixed effects meta-analysis with risk ratio of new onset or worsening tics in children treated with psychostimulants compared to placebo. We used strati?ed subgroup analysis and meta-regression to examine the effects of stimulant type, dose, duration of treatment, recorder of side effect data, trial design, and mean age of participants on the measured risk of tics.
We identified 22 studies involving 2,385 children with ADHD for inclusion in our meta-analysis. New onset tics or worsening of tic symptoms were commonly reported in the psychostimulant (event rate=5.7% (95% CI: 3.7% to 8.6%), I2 =72%, p<0.001) and placebo groups (event rate=6.5% (95% CI: 4.4% to 9.5%), I2 =64%, p<0.001). The risk of new onset or worsening of tics associated with psychostimulant treatment was similar to that observed with placebo (risk ratio=0.99 (95% CI: 0.78 to 1.27), z=-0.05, p=0.96). Type of psychostimulant, dose, duration of treatment, recorder of side effects, and participant age did not affect risk of new onset or worsening of tics. Crossover studies were associated with a significantly greater measured risk of tics with psychostimulant use compared to parallel group trials.
Meta-analysis of controlled trials does not support an association between new onset or worsening of tics and psychostimulant use. Clinicians may want to consider re-challenging children who report new onset or worsening of tics with psychostimulant use, as these symptoms are much more likely to be coincidental rather than caused by psychostimulants.
Format
Books / Online / Dissertations & Theses
Language
English
Added to Catalog
January 19, 2017
Thesis note
Thesis (M.D.)--Yale University, 2016.
Also listed under
Yale University. School of Medicine.
Citation

Available from:

Online
Loading holdings.
Unable to load. Retry?
Loading holdings...
Unable to load. Retry?